Richter BioLogics has officially opened its new cGMP biopharmaceutical facility for business.
Situated in Bovenau, the site will focus on the manufacture of protein-based and plasmid DNA-based products for both clinical trials and commercial indications.
Standing at 10,000m2, the facility contains both 300L and 1500L production lines, allowing customers to manufacture different products simultaneously.
The company claims the site is capable of producing up to 120 batches per year.
Richter's biologics manufacturing centre also contains laboratories for analytical testing, as well as a dedicated warehouse space for the storage of protein and DNA-based drug products.
Richter BioLogics' Managing Director, Dr Kai Pohlmeyer, commented: “Putting the plant into operation represents a major milestone in the implementation of Richter BioLogics' growth strategy."
"This is one of our largest investments in the last decade, and we aim to meet the global biologics demand while supplying the pharmaceutical industry with the highest quality biopharmaceutical products. We also increase our flexibility, one of our biggest and most valued strengths."
Head of the Biotech division of Gedeon Richter, Dr Erik Bogsch, added: "This novel facility — together with our existing sites in Hungary — will allow us to provide a fully integrated R&D and manufacturing service to our European customers and beyond, ultimately benefitting patients worldwide."
The new production facility was inaugurated by Daniel Günther, Minister-President of the State of Schleswig-Holstein, Daniel Ambrock, Mayor of Bovenau, on behalf of the Gedeon Richter Group.
